IL291727B1 - Method and compositions for treating coronavirus infection - Google Patents

Method and compositions for treating coronavirus infection

Info

Publication number
IL291727B1
IL291727B1 IL291727A IL29172722A IL291727B1 IL 291727 B1 IL291727 B1 IL 291727B1 IL 291727 A IL291727 A IL 291727A IL 29172722 A IL29172722 A IL 29172722A IL 291727 B1 IL291727 B1 IL 291727B1
Authority
IL
Israel
Prior art keywords
compositions
coronavirus infection
treating coronavirus
treating
infection
Prior art date
Application number
IL291727A
Other languages
Hebrew (he)
Other versions
IL291727B2 (en
IL291727A (en
Original Assignee
Phoenix Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by Phoenix Biotechnology Inc filed Critical Phoenix Biotechnology Inc
Publication of IL291727A publication Critical patent/IL291727A/en
Publication of IL291727B1 publication Critical patent/IL291727B1/en
Publication of IL291727B2 publication Critical patent/IL291727B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
IL291727A 2020-03-31 2022-03-27 Method and compositions for treating coronavirus infection IL291727B2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US202063051576P 2020-07-14 2020-07-14

Publications (3)

Publication Number Publication Date
IL291727A IL291727A (en) 2022-05-01
IL291727B1 true IL291727B1 (en) 2023-03-01
IL291727B2 IL291727B2 (en) 2023-07-01

Family

ID=77930101

Family Applications (2)

Application Number Title Priority Date Filing Date
IL277315A IL277315B (en) 2020-03-31 2020-09-13 Methods and composition for treating coronavirus infection
IL291727A IL291727B2 (en) 2020-03-31 2022-03-27 Method and compositions for treating coronavirus infection

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL277315A IL277315B (en) 2020-03-31 2020-09-13 Methods and composition for treating coronavirus infection

Country Status (8)

Country Link
JP (2) JP7153083B2 (en)
KR (2) KR20220151038A (en)
IL (2) IL277315B (en)
MX (2) MX2020009095A (en)
RU (1) RU2020130238A (en)
SG (1) SG11202105728YA (en)
TW (2) TWI753747B (en)
WO (1) WO2021201903A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CA3228041A1 (en) * 2021-08-16 2023-02-23 Phoenix Biotechnology, Inc. Method and compositions for treating animal viral infections
WO2023212353A1 (en) * 2022-04-29 2023-11-02 Emory University Viral entry inhibitors derived from botanicals
CN115364136A (en) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） Application of Crassulaceae plant extract in preparing medicine for resisting novel coronavirus and influenza virus infection

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
IN165073B (en) 1986-05-13 1989-08-12 Ziya Ozel Huseyin
JPS6333341A (en) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd Treatment of glycoside
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
NZ507791A (en) 1998-05-19 2003-12-19 Res Dev Foundation Triterpene compositions from Acacia victoriae and methods for use thereof
JP2002526452A (en) 1998-09-24 2002-08-20 オゼル・ファーマスーティカルズ・インコーポレイテッド Oleander extract, its pharmaceutical composition and its preparation method
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
WO2002016395A1 (en) 2000-08-18 2002-02-28 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer and hiv
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
DE60204078T2 (en) 2001-04-09 2006-01-26 Loders Croklaan B.V. Concentrate of triterpenes
CA2446748C (en) 2001-05-11 2011-03-08 University Of Ottawa Anxiolytic marcgraviaceae compositions containing betulinic acid, betulinic acid derivatives, and methods
CA2443630A1 (en) 2001-06-18 2002-12-27 S.A.V. Virex Co Ltd. Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
JP2006508126A (en) 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド Protein-stabilized liposome formulation of pharmaceutical formulation
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
RU2387665C2 (en) 2004-03-17 2010-04-27 Панакос Фармасьютикалз, Инк. Pharmaceutical salts of 3-o-(3',3-dimethylsuccinyl) betulinic acid
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
US20070016176A1 (en) 2004-08-13 2007-01-18 Dmitri Boutoussov Laser handpiece architecture and methods
BRPI0519948A2 (en) 2005-02-09 2009-12-01 Dabur Pharma Ltd compound, process for preparing a compound, pharmaceutical composition and method of treating cancer in a mammal
EP1869062A1 (en) 2005-03-29 2007-12-26 The Regents of the University of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
WO2006133314A2 (en) 2005-06-08 2006-12-14 Regents Of The University Of Minnesota Synthesis of betulonic and betulinic aldehydes
AU2006256351B2 (en) 2005-06-10 2011-08-04 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007078848A2 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
WO2008063318A2 (en) 2006-10-12 2008-05-29 The Texas A & M University System And Safe Et Al Betulinic acid, derivatives and analogs thereof and uses therefor
TW200837074A (en) 2006-11-03 2008-09-16 Panacos Pharmaceuticals Inc Extended triterpene derivatives
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
WO2009064657A1 (en) 2007-11-13 2009-05-22 Phoenix Biotechnology Inc. Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside
KR101782020B1 (en) 2008-04-18 2017-09-26 리타 파마슈티컬스 잉크. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
TWI442925B (en) 2008-04-18 2014-07-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring
ES2703274T3 (en) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Antioxidant modulators of inflammation: oleanolic acid derivatives with amino and other modifications in C-17
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
WO2010028487A1 (en) 2008-09-10 2010-03-18 Université Du Québec À Chicoutimi Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
US8524286B2 (en) 2008-10-14 2013-09-03 Nerium Biotechnology, Inc. Plant extraction method and compositions
WO2010053817A1 (en) 2008-11-04 2010-05-14 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (en) 2009-11-23 2012-06-27 张南 23-hydroxybetulinic acid derivatives as well as preparation methods and application thereof
WO2011064710A1 (en) 2009-11-30 2011-06-03 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
MX2012007977A (en) 2010-01-11 2012-08-23 Phoenix Biotechnology Inc Method of treating neurological conditions with cardiac glycosides.
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
TWI386415B (en) 2010-02-02 2013-02-21 Univ Kaohsiung Medical Ursolic acid derivative and pharmaceutical composition thereof
TWI410431B (en) 2010-12-22 2013-10-01 Ind Tech Res Inst Use of oleanolic acid derivatives in the manufacture of a medicament to prevent or treat hepatitis c
US20140221328A1 (en) 2011-01-10 2014-08-07 Bandi Parthasaradhi Reddy Pharmaceutically acceptable salts of novel betulinic acid derivatives
ES2552512T3 (en) 2011-01-31 2015-11-30 Bristol-Myers Squibb Company C-28 amines of C-3 modified betulinic acid derivatives as inhibitors of human immunodeficiency virus maturation
CN102558280B (en) 2011-11-18 2014-09-17 温州大学 Method for producing 30-halogenated betulinic acid
JP6211527B2 (en) 2011-12-01 2017-10-11 ハンジョウ ベンシェン ファーマシューティカル シーオー．， エルティーディー．Ｈａｎｇｚｈｏｕ Ｂｅｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． 2-substituted oleanolic acid derivatives, their preparation and use
WO2013079024A1 (en) 2011-12-01 2013-06-06 杭州本生药业有限公司 Oleanolic acid amidate derivatives, preparation methods and uses thereof
US20150119373A1 (en) 2012-04-24 2015-04-30 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
CN104684883A (en) 2012-08-14 2015-06-03 内克索利戈有限公司 Novel ursolic acid derivative and method for preparing same
BR112015005200B1 (en) 2012-09-10 2022-07-05 Reata Pharmaceuticals, Inc COMPOUND DERIVED FROM C17-HETEROARYL OF OLEANOLIC ACID, PHARMACEUTICAL COMPOSITION COMPRISING SUCH COMPOUND AND USE THEREOF
LT2892912T (en) 2012-09-10 2019-07-10 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
WO2014130810A1 (en) 2013-02-25 2014-08-28 Bristol-Myers Squibb Company C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
US20190216835A1 (en) * 2016-06-09 2019-07-18 University Of Massachusetts Inhibition of Zika Virus Infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
WO2018053123A1 (en) 2016-09-14 2018-03-22 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
CA3075729A1 (en) 2017-09-14 2019-03-21 Phoenix Biotechnology, Inc. Use of oleandrin to treatn viral infection

Also Published As

Publication number Publication date
TW202137991A (en) 2021-10-16
KR102464428B1 (en) 2022-11-04
RU2020130238A3 (en) 2022-03-14
KR20210124010A (en) 2021-10-14
TWI790048B (en) 2023-01-11
IL291727B2 (en) 2023-07-01
JP2022522074A (en) 2022-04-14
IL291727A (en) 2022-05-01
IL277315A (en) 2021-09-30
JP2022186737A (en) 2022-12-15
TWI753747B (en) 2022-01-21
TW202211926A (en) 2022-04-01
RU2020130238A (en) 2022-03-14
SG11202105728YA (en) 2021-11-29
KR20220151038A (en) 2022-11-11
IL277315B (en) 2022-05-01
MX2020009095A (en) 2022-07-28
WO2021201903A1 (en) 2021-10-07
JP7153083B2 (en) 2022-10-13
MX2022009176A (en) 2022-08-17

Similar Documents

Publication Publication Date Title
IL291727A (en) Method and compositions for treating coronavirus infection
EP4267582A4 (en) Methods and modified nucleosides for treating coronavirus infections
EP4100019A4 (en) Method for treating coronavirus infections
EP4136254A4 (en) Ace2-targeted compositions and methods for treating covid-19
EP4093758A4 (en) Methods and compositions for treating and preventing viral infection
EP4125937A4 (en) Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
EP4096675A4 (en) Compositions and methods for treating long covid
EP4103164A4 (en) Compounds for treating coronavirus infection
IL299295A (en) Methods and compositions for treating hemophilia
ZA202206163B (en) Methods of treating coronavirus
EP4164695A4 (en) Compositions and methods for treating gjb2-associated hearing loss
EP4132539A4 (en) Compositions and methods for treating bacterial infections
IL307872A (en) Novel compositions and methods for treating coronavirus infections
EP4114176A4 (en) Sterilization compositions and methods for using thereof
EP4103192A4 (en) Compositions and methods for treating coronavirus infections
EP4009981C0 (en) Method and compositions for treating coronavirus infection
EP4120863A4 (en) Method for treatment of coronavirus infection
EP4153609A4 (en) Compositions and methods for prevention of coronavirus infection
EP4138862A4 (en) Compositions and methods for treating upper respiratory infections
EP4114438A4 (en) Methods and compositions for treating muscle atrophy
EP4132503A4 (en) Methods for treatment of coronavirus infections
EP4157260A4 (en) Compositions and methods for treating headaches
ZA202110332B (en) Composition for treating coronavirus infection
IL277546A (en) Methods and compositions for treating coronaviral infections
GB202215010D0 (en) Compositions for preventing and treating infection